Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen
Publikationen
Ergebnisse pro Seite:  10

Kadioglu, Onat; Saeed, Mohamed E. M.; Greten, Henry J. et al.

Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. Bd. 84. H. 4. 2021 S. 1086-1089


Beltzig, L.; Stratenwerth, B.; Christmann, M. et al.

Identification of senolytic agents for sequential treatment of glioblastoma with temozolomide

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. Bd. 394. H. SUPPL 1. 2021 S. S30-S30


Berte, Nancy; Eich, Marcus; Heylmann, Daniel et al.

Impaired DNA repair in mouse monocytes compared to macrophages and precursors

DNA REPAIR. Bd. 98. 2021


Hassan, Zonera; Schneeweis, Christian; Wirth, Matthias et al.

Important role of Nfkb2 in the Kras(G12D)-driven carcinogenesis in the pancreas

PANCREATOLOGY. Bd. 21. H. 5. 2021 S. 912-919


Wachholz, Vanessa; Mustafa, Al-Hassan M.; Zeyn, Yanira et al.

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3

ARCHIVES OF TOXICOLOGY. Bd. 96. H. 1. 2021 S. 177-193


Reich, Thomas R.; Schwarzenbach, Christian; Vilar, Juliana Brandstetter et al.

Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination

CELLULAR AND MOLECULAR LIFE SCIENCES. Bd. 78. H. 14. 2021 S. 5587-5604


Marx, Christian; Sonnemann, Juergen; Beyer, Mandy et al.

Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells

MOLECULAR ONCOLOGY. Bd. 15. H. 12. 2021 S. 3404-3429


Haas, Bodo; Ciftcioglu, Janine; Jermar, Sanja et al.

Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Bd. 147. H. 3. 2021 S. 779-792


Stratenwerth, Bjoern; Geisen, Susanne M.; He, Yang et al.

Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses

MOLECULAR CANCER THERAPEUTICS. Bd. 20. H. 10. 2021 S. 1789-1799